1.
Takeda DY, Spisák S, Seo J-H, et al. A Somatically Acquired Enhancer of the Androgen Receptor Is a Noncoding Driver in Advanced Prostate Cancer. Cell. 2018;174(2):422-432.e13. doi:10.1016/j.cell.2018.05.037.
1.
Viswanathan SR, Ha G, Hoff AM, et al. Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing. Cell. 2018;174(2):433-447.e19. doi:10.1016/j.cell.2018.05.036.
1.
Sheahan AV, Ellis L. Epigenetic reprogramming: A key mechanism driving therapeutic resistance. Urol Oncol. 2018;36(8):375-379. doi:10.1016/j.urolonc.2017.12.021.
1.
Miyahira AK, Sharp A, Ellis L, et al. Prostate cancer research: The next generation; report from the 2019 Coffey-Holden Prostate Cancer Academy Meeting. Prostate. 2020;80(2):113-132. doi:10.1002/pros.23934.
1.
Van Allen EM, Foye A, Wagle N, et al. Successful whole-exome sequencing from a prostate cancer bone metastasis biopsy. Prostate Cancer Prostatic Dis. 2014;17(1):23-7. doi:10.1038/pcan.2013.37.
1.
Hsieh C-L, Botta G, Gao S, et al. PLZF, a tumor suppressor genetically lost in metastatic castration-resistant prostate cancer, is a mediator of resistance to androgen deprivation therapy. Cancer Res. 2015;75(10):1944-8. doi:10.1158/0008-5472.CAN-14-3602.
1.
Robinson D, Van Allen EM, Wu Y-M, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161(5):1215-28. doi:10.1016/j.cell.2015.05.001.
1.
Beltran H, Prandi D, Mosquera JM, et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med. 2016;22(3):298-305. doi:10.1038/nm.4045.
1.
Mullane SA, Van Allen EM. Precision medicine for advanced prostate cancer. Curr Opin Urol. 2016;26(3):231-9. doi:10.1097/MOU.0000000000000278.
1.
Groner AC, Cato L, de Tribolet-Hardy J, et al. TRIM24 Is an Oncogenic Transcriptional Activator in Prostate Cancer. Cancer Cell. 2016;29(6):846-58. doi:10.1016/j.ccell.2016.04.012.